Somatostatin Receptor-Directed PET/CT Can Differentiate Between Different Subtypes of Head and Neck Paragangliomas.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
23
10
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Given their neuroendocrine origin, head and neck paragangliomas (HNPGLs) can be imaged with somatostatin receptor (SSTR)-directed PET/CT. We aimed to determine whether the in vivo PET signal can differentiate between varying HNPGL subtypes. Fourteen patients with HNPGL received pretherapeutic SSTR-PET/CTs using 68 Ga-DOTATOC. Six (42.9%) patients had a jugular paraganglioma (PGL-J), 5 (35.7%) were diagnosed with carotid paraganglioma (PGL-Cs), and the remaining 3 patients (21.4%) had PGL-C with pathogenic SDHx germline variants (PGL-C-SDH). A visual and quantitative assessment of the primary tumor on SSTR-PET was performed, including SUV max and target-to-background ratio (TBR). Quantitative values were then compared between subgroups of patients affected with different HNPGL entities. On visual assessment, all primary HNPGLs could be identified on SSTR-PET/CT. Quantification of HNPGL revealed substantially elevated SUV max in PGL-J (101.7 ± 58.5) when compared with PGL-C-SDH (13.4 ± 5.6, P < 0.05), but not when compared with PGL-C (66.7 ± 27.3, P = 0.4; PGL-C vs PGL-C-SDH, P = 0.2). TBR of PGL-J (202.9 ± 82.2), however, further differentiated between PGL-C (95.7 ± 45.4, P < 0.05) and PGL-C-SDH (20.4 ± 12.2, P < 0.01; PGL-C vs PGL-C-SDH, P = 0.3). Moreover, whole-body readout revealed metastases in 2/3 (66.7%) of PGL-C-SDH patients, with a single SSTR-expressing skeletal lesion in one subject and bipulmonary lesions in the other patient. In patients with HNPGL, SSTR-PET/CT identified the primary and metastatic disease and provides substantially elevated TBR, indicating excellent image contrast. PET-based quantification can also differentiate between varying HNPGL subtypes.
Sections du résumé
BACKGROUND
BACKGROUND
Given their neuroendocrine origin, head and neck paragangliomas (HNPGLs) can be imaged with somatostatin receptor (SSTR)-directed PET/CT. We aimed to determine whether the in vivo PET signal can differentiate between varying HNPGL subtypes.
PATIENTS AND METHODS
METHODS
Fourteen patients with HNPGL received pretherapeutic SSTR-PET/CTs using 68 Ga-DOTATOC. Six (42.9%) patients had a jugular paraganglioma (PGL-J), 5 (35.7%) were diagnosed with carotid paraganglioma (PGL-Cs), and the remaining 3 patients (21.4%) had PGL-C with pathogenic SDHx germline variants (PGL-C-SDH). A visual and quantitative assessment of the primary tumor on SSTR-PET was performed, including SUV max and target-to-background ratio (TBR). Quantitative values were then compared between subgroups of patients affected with different HNPGL entities.
RESULTS
RESULTS
On visual assessment, all primary HNPGLs could be identified on SSTR-PET/CT. Quantification of HNPGL revealed substantially elevated SUV max in PGL-J (101.7 ± 58.5) when compared with PGL-C-SDH (13.4 ± 5.6, P < 0.05), but not when compared with PGL-C (66.7 ± 27.3, P = 0.4; PGL-C vs PGL-C-SDH, P = 0.2). TBR of PGL-J (202.9 ± 82.2), however, further differentiated between PGL-C (95.7 ± 45.4, P < 0.05) and PGL-C-SDH (20.4 ± 12.2, P < 0.01; PGL-C vs PGL-C-SDH, P = 0.3). Moreover, whole-body readout revealed metastases in 2/3 (66.7%) of PGL-C-SDH patients, with a single SSTR-expressing skeletal lesion in one subject and bipulmonary lesions in the other patient.
CONCLUSIONS
CONCLUSIONS
In patients with HNPGL, SSTR-PET/CT identified the primary and metastatic disease and provides substantially elevated TBR, indicating excellent image contrast. PET-based quantification can also differentiate between varying HNPGL subtypes.
Identifiants
pubmed: 37756444
doi: 10.1097/RLU.0000000000004870
pii: 00003072-202311000-00001
pmc: PMC10581414
doi:
Substances chimiques
Receptors, Somatostatin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
923-927Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: speaker honoraria from Novartis/AAA (R.A.W.), advisory board work for Novartis/AAA (R.A.W.). No conflict of interest was reported by any of the other authors. This study was partially funded by the German Research Foundation (453989101, T.H., R.A.W.; 507803309, R.A.W.).
Références
Ekberg T, Haylock AK, Wanhainen A, et al. Paraganglioma (glomus tumour) of the head and neck, a rare and demanding diagnosis [in Swedish]. Lakartidningen . 2022;119.
Sandow L, Thawani R, Kim MS, et al. Paraganglioma of the head and neck: a review. Endocr Pract . 2023;29:141–147.
Williams MD. Paragangliomas of the head and neck: an overview from diagnosis to genetics. Head Neck Pathol . 2017;11:278–287.
Moskovic DJ, Smolarz JR, Stanley D, et al. Malignant head and neck paragangliomas: is there an optimal treatment strategy? Head Neck Oncol . 2010;2:23.
Majewska A, Budny B, Ziemnicka K, et al. Head and neck paragangliomas—a genetic overview. Int J Mol Sci . 2020;21.
Gujrathi CS, Donald PJ. Current trends in the diagnosis and management of head and neck paragangliomas. Curr Opin Otolaryngol Head Neck Surg . 2005;13:339–342.
Pellitteri PK, Rinaldo A, Myssiorek D, et al. Paragangliomas of the head and neck. Oral Oncol . 2004;40:563–575.
Neves F, Huwart L, Jourdan G, et al. Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol . 2008;29:883–889. doi:10.3174/ajnr.A0948.
doi: 10.3174/ajnr.A0948
Kratochwil C, Stefanova M, Mavriopoulou E, et al. SUV of [ 68 Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol . 2015;17:313–318.
Han S, Suh CH, Woo S, et al. Performance of 68 Ga-DOTA-conjugated somatostatin receptor–targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med . 2019;60:369–376.
Hennrich U, Benešova M. [ 68 Ga]Ga-DOTA-TOC: the first FDA-approved 68 Ga-radiopharmaceutical for PET imaging. Pharmaceuticals (Basel) . 2020;13:38. doi:10.3390/ph13030038.
doi: 10.3390/ph13030038
Serfling SE, Zhi Y, Megerle F, et al. Somatostatin receptor–directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma. Endocrine . 2022;78:169–176. doi:10.1007/s12020-022-03116-6.
doi: 10.1007/s12020-022-03116-6
Kosmala A, Serfling SE, Schlötelburg W, et al. Impact of 68 Ga-FAPI-04 PET/CT on staging and therapeutic management in patients with digestive system tumor. Clin Nucl Med . 2022;48:35–42.
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging . 2017;44:1588–1601.
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging . 2013;40:800–816.
Sharma P, Thakar A, Suman KCS, et al. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med . 2013;54:841–847.
Gottfried ON, Liu JK, Couldwell WT. Comparison of radiosurgery and conventional surgery for the treatment of glomus jugulare tumors. Neurosurg Focus 2004;17:E4, 22, 30.
Hu K, Persky MS. The multidisciplinary management of paragangliomas of the head and neck, Part 2. Oncology (Williston Park) . 2003;17:1143–1153; discussion 1154, 1158, 1161.
Hu K, Persky MS. Multidisciplinary management of paragangliomas of the head and neck, part 1. Oncology (Williston Park) . 2003;17:983–993.
Papaspyrou K, Mewes T, Rossmann H, et al. Head and neck paragangliomas: report of 175 patients (1989-2010). Head Neck . 2012;34:632–637.
Maturo S, Brennan J. Baroreflex failure: a rare complication of carotid paraganglioma surgery. Laryngoscope . 2006;116:829–830.
Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol . 2021;22:1752–1763.
Roll W, Müther M, Sporns PB, et al. Somatostatin receptor–targeted radioligand therapy in head and neck paraganglioma. World Neurosurg . 2020;143:e391–e399.
Estevao R, Duarte H, Lopes F, et al. Peptide receptor radionuclide therapy in head and neck paragangliomas—report of 14 cases. Rev Laryngol Otol Rhinol (Bord) . 2015;136:155–158.
Contrera KJ, Yong V, Reddy CA, et al. Recurrence and progression of head and neck paragangliomas after treatment. Otolaryngol Head Neck Surg . 2020;162:504–511.
Hanscheid H, Lapa C, Buck AK, et al. Dose mapping after endoradiotherapy with (177)Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med . 2018;59:75–81.
Wang K, Crona J, Beuschlein F, et al. Targeted therapies in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab . 2022;107:2963–2972.
Prinzi N, Corti F, Torchio M, et al. Metastatic pheochromocytomas and paragangliomas: where are we? Tumori . 2022;108:526–540.
Kaemmerer D, Sanger J, Arsenic R, et al. Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large set of paragangliomas. Oncotarget . 2017;8:89958–89969.